Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient - Possible relationship to intestinal P-glycoprotein activity

被引:51
作者
Kaplan, B
Lown, K
Craig, R
Abecassis, M
Kaufman, D
Leventhal, J
Stuart, F
Meier-Kriesche, HU
Fryer, J
机构
[1] Northwestern Univ, Sch Med, Dept Surg, Div Transplantat, Chicago, IL 60611 USA
[2] Northwestern Univ, Sch Med, Dept Med, Div Transplantat, Chicago, IL 60611 USA
[3] St Barnabas Med Ctr, Dept Med, Div Nephrol, Livingston, NJ USA
[4] Univ Michigan, Dept Med, Div Gastroenterol, Ann Arbor, MI 48109 USA
关键词
D O I
10.1097/00007890-199901270-00026
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
With intestine transplants the allograft is dependent on itself for maintenance of adequate immunosuppression. We evaluated an intestinal transplant recipient who required very large doses of either tacrolimus or cyclosporine emulsion to achieve acceptable blood concentrations. Pharmacokinetic studies revealed bioavailabilities of 2% and 6% respectively, while D-xylose and B12 absorption were found to be within normal limits and fecal fat was only slightly increased, suggesting that there was a selective absorptive defect for these drugs, Biopsies of the allograft ileum revealed a high P-glycoprotein activity compared to the jejunum or to intestinal biopsies from other normal subjects, This may be a contributing factor to poor immunosuppressive drug absorption in this patient and others.
引用
收藏
页码:333 / 335
页数:3
相关论文
共 8 条
[1]   THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE [J].
GOMEZ, DY ;
WACHER, VJ ;
TOMLANOVICH, SJ ;
HEBERT, MF ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :15-19
[2]   Current results of intestinal transplantation [J].
Grant, D .
LANCET, 1996, 347 (9018) :1801-1803
[3]   PHARMACOKINETICS OF FK506 AFTER INTRAVENOUS AND ORAL-ADMINISTRATION IN PATIENTS AWAITING RENAL-TRANSPLANTATION [J].
GRUBER, SA ;
HEWITT, JM ;
SORENSON, AL ;
BARBER, DL ;
BOWERS, L ;
RYNDERS, G ;
ARRAZOLA, L ;
MATAS, AJ ;
ROSENBERG, ME ;
CANAFAX, DM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (08) :859-864
[4]  
KAHAN BD, 1990, NEW ENGL J MED, V322, P1530
[5]  
LEE C, 1993, CLIN PHARMACOL THER, V53, P238
[6]  
LEE KKW, 1990, TRANSPLANT P, V22, P78
[7]   Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine [J].
Lown, KS ;
Mayo, RR ;
Leichtman, AB ;
Hsiao, HL ;
Turgeon, DK ;
SchmiedlinRen, P ;
Brown, MB ;
Guo, WS ;
Rossi, SJ ;
Benet, LZ ;
Watkins, PB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) :248-260
[8]   IMPROVED DOSE LINEARITY OF CYCLOSPORINE PHARMACOKINETICS FROM A MICROEMULSION FORMULATION [J].
MUELLER, EA ;
KOVARIK, JM ;
VANBREE, JB ;
TETZLOFF, W ;
GREVEL, J ;
KUTZ, K .
PHARMACEUTICAL RESEARCH, 1994, 11 (02) :301-304